EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Cardiovascular Peptides
This cluster covers five cardiovascular peptides—four FDA-approved drugs used from acute coronary intervention to heart failure management and migraine prevention, plus one cautionary tale from the heart failure pipeline.
Bivalirudin, Eptifibatide, Nesiritide, and CGRP have extensive clinical trial histories and well-characterized safety profiles. Relaxin is the outlier—a Tier 2 compound with spectacular Phase III biology that failed to replicate in the largest confirmatory trial ever run for a heart failure drug. Its presence here rounds out the cluster’s story: not just what works, but what the evidence looked like it would work and didn’t.
Cluster at a Glance
|
5 Compounds Covered |
4 Approved Drug |
1 Clinical Trials |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
BLUF: Bottom Line Up Front
Four FDA-approved drugs and one cautionary tale. Bivalirudin and Eptifibatide prevent blood clots during cardiac catheterization. Nesiritide was developed for acute heart failure, though its clinical utility has been debated since ASCEND-HF showed no mortality benefit. CGRP is the biological target behind the newest migraine drugs (erenumab, galcanezumab, fremanezumab). Relaxin is the outlier—a pregnancy hormone that stunned cardiologists with a 37% mortality reduction in heart failure, then broke their hearts when the 6,600-patient confirmatory trial found absolutely nothing. Three companies are still pursuing it. This cluster shows the full spectrum: drugs that work, drugs that work but don’t save lives, and a drug that looked like it would change everything until it didn’t.
In This Article
Compounds in This Cluster
All 5 compounds in the Cardiovascular Peptides cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 4
The Antithrombotic Agents
FDA-approved peptides used during cardiac procedures and acute coronary syndromes to prevent clot formation.
Group 2 of 4
The Heart Failure Drug
A recombinant natriuretic peptide for acute decompensated heart failure.
|
Group 3 of 4
The Migraine Target
The neuropeptide whose blockade created a new class of preventive migraine therapy.
|
Group 4 of 4
The Heart Failure Cautionary Tale
A pregnancy hormone with beautiful cardiovascular biology, a spectacular initial trial, and a definitive failure to replicate—the compound that taught the cardiology world that a 37% mortality reduction can vanish.
|
How These Compounds Relate
These five compounds operate in distinct cardiovascular territories. Bivalirudin and Eptifibatide are both antithrombotic agents used during cardiac catheterization, but they work through different targets: Bivalirudin directly inhibits thrombin (the enzyme that converts fibrinogen to fibrin), while Eptifibatide blocks the glycoprotein IIb/IIIa receptor that mediates platelet-to-platelet bridging. In practice, they represent alternative strategies for the same clinical moment—keeping blood from clotting during a coronary intervention.
Nesiritide addresses a completely different problem: the fluid overload and vasoconstriction of acute heart failure. As a recombinant BNP, it mimics the body’s own natriuretic peptide signaling to reduce preload and promote sodium excretion. Its clinical history is instructive—initial enthusiasm gave way to controversy when the large ASCEND-HF trial showed symptomatic improvement but no mortality reduction.
CGRP stands apart as both a cardiovascular peptide and a pain target. Its vasodilatory potency made it a candidate for cardiovascular applications, but its greatest therapeutic impact has been in the migraine space, where anti-CGRP monoclonal antibodies have provided the first disease-specific preventive therapy for a condition that affects over a billion people worldwide.
Relaxin is the cluster’s cautionary tale—and its most fascinating pharmacological story. A two-chain insulin-family hormone known primarily for loosening ligaments during pregnancy, it also relaxes blood vessels (via nitric oxide), protects kidneys, and reverses organ fibrosis. Novartis developed recombinant serelaxin and ran RELAX-AHF (2013, n=1,161), which showed a striking 37% reduction in 180-day mortality. The confirmatory trial, RELAX-AHF-2 (2019, n=6,600), found no benefit on any endpoint. The program was discontinued. Three new companies—Relaxera, Tectonic Therapeutic, and AstraZeneca—are pursuing modified relaxin-pathway drugs with different dosing strategies. Whether RELAX-AHF was a false positive or RELAX-AHF-2 asked the wrong question remains one of cardiovascular drug development’s open questions.
| Shared Mechanism | Compounds |
|
Direct Thrombin Inhibition Blocks thrombin's enzymatic conversion of fibrinogen to fibrin, preventing clot formation during coronary procedures. |
Bivalirudin |
|
Platelet Aggregation Inhibition Blocks the GPIIb/IIIa receptor on platelets, preventing the final common pathway of clot formation. |
Eptifibatide |
|
Natriuretic Peptide Signaling Activates guanylate cyclase receptors to promote vasodilation, natriuresis, and reduced cardiac preload. |
Nesiritide |
|
Vasodilation / Pain Signaling Potent vasodilator and pain mediator whose blockade prevents migraine through reduced trigeminovascular activation. |
CGRP |
|
Multi-Target Vasodilation / Anti-Fibrosis Relaxes blood vessels via nitric oxide, protects kidneys through hemodynamic effects, and reverses organ fibrosis via MMP upregulation and TGF-β inhibition—addressing multiple heart failure pathways simultaneously. |
Relaxin |
Plain English
Five compounds, five different stories in your cardiovascular system. Two (Bivalirudin, Eptifibatide) are used in hospitals during heart procedures to stop blood clots from forming. One (Nesiritide) helps the heart and kidneys manage fluid overload in acute heart failure, though its star has faded since a big trial showed it helps symptoms but does not save lives. CGRP is the molecule behind the newest migraine drugs—blocking it prevents migraines in many patients for the first time without daily pills. And Relaxin is the pregnancy hormone that looked like it could revolutionize heart failure treatment—until the biggest study ever run on it found no benefit at all. Three companies are still trying to make it work.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.